Immunotherapy combo shows promise for Hard-to-Treat colorectal cancer
NCT ID NCT03926338
First seen Nov 20, 2025 · Last updated May 13, 2026 · Updated 20 times
Summary
This study is for people with a specific type of colorectal cancer (dMMR/MSI-H) that hasn't spread far. It tests giving an immunotherapy drug (toripalimab) with or without an anti-inflammatory drug (celecoxib) before surgery. The goal is to see if this approach can shrink or eliminate the tumor before surgery and improve long-term outcomes. About 270 adults aged 18-75 with this cancer type are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.